Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma

References

1. 1.↵
   1. Louis DN,
   2. Ohgaki H,
   3. Wiestler OD,
   4. et al

   . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109. Epub 2007 Jul 6

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Castillo M,
   2. Smith JK,
   3. Kwock L,
   4. et al

   . Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001;22:60–64

   Abstract/FREE Full Text
3. 3.↵
   1. Guo AC,
   2. Cummings TJ,
   3. Dash RC,
   4. et al

   . Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177–83

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Higano S,
   2. Yun X,
   3. Kumabe T,
   4. et al

   . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Saksena S,
   2. Jain R,
   3. Narang J,
   4. et al

   . Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging 2010;32:788–95

   CrossRefPubMed
6. 6.↵
   1. Murakami R,
   2. Sugahara T,
   3. Nakamura H,
   4. et al

   . Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007;243:493–99

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Jain R,
   2. Scarpace LM,
   3. Ellika S,
   4. et al

   . Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion-weighted imaging as an imaging biomarker. J Neurooncol 2010;96:423–31

   CrossRefPubMed
8. 8.↵
   1. Rieger J,
   2. Bahr O,
   3. Muller K,
   4. et al

   . Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2010;99:49–56

   CrossRefPubMed
9. 9.↵
   1. Mohile NA,
   2. Abrey LE

   . Assessment of treatment response to bevacizumab (bev) with MRI in recurrent malignant glioma (MG) [abstract MA-05]. Neuro Oncol 2007;9:516
10. 10.↵
    1. Pope WB,
    2. Kim HJ,
    3. Huo J,
    4. et al

    . Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182–89

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Gerstner ER,
    2. Frosch MP,
    3. Batchelor TT

    . Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010;28:e91–93

    FREE Full Text
12. 12.↵
    1. Gerstner ER,
    2. Chen PJ,
    3. Wen PY,
    4. et al

    . Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 2010;12:466–72. Epub 2010 Jan 22

    Abstract/FREE Full Text
13. 13.↵
    1. Gutin PH,
    2. Iwamoto FM,
    3. Beal K,
    4. et al

    . Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156–63

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Larsson HB,
    2. Tofts PS

    . Measurement of blood-brain barrier permeability using dynamic Gd-DTPA scanning: a comparison of methods. Magn Reson Med 1992;24:174–76

    PubMed
15. 15.↵
    1. Law M,
    2. Oh S,
    3. Johnson G,
    4. et al

    . Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006;58:1099–107. discussion 1099–107

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Young RJ,
    2. Knopp EA

    . Brain MRI: tumor evaluation. J Magn Reson Imaging 2006;24:709–24

    CrossRefPubMed
17. 17.↵
    1. Al-Okaili RN,
    2. Krejza J,
    3. Wang S,
    4. et al

    . Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 2006;26(suppl 1):S173–89

    CrossRefPubMed
18. 18.↵
    1. Wetzel SG,
    2. Cha S,
    3. Johnson G,
    4. et al

    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Wen PY,
    2. Macdonald DR,
    3. Reardon DA,
    4. et al

    . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72. Epub 2010 Mar 15

    Abstract/FREE Full Text
20. 20.↵
    1. Hormigo A,
    2. Gutin PH,
    3. Rafii S

    . Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell 2007;11:6–8

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Sugahara T,
    2. Korogi Y,
    3. Kochi M,
    4. et al

    . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53–60

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Gupta RK,
    2. Cloughesy TF,
    3. Sinha U,
    4. et al

    . Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215–26

    CrossRefPubMed
23. 23.↵
    1. Gupta RK,
    2. Sinha U,
    3. Cloughesy TF,
    4. et al

    . Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 1999;41:2–7

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Bulakbasi N,
    2. Guvenc I,
    3. Onguru O,
    4. et al

    . The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors. J Comput Assist Tomogr 2004;28:735–46

    CrossRefPubMed
25. 25.↵
    1. Fan GG,
    2. Deng QL,
    3. Wu ZH,
    4. et al

    . Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? Br J Radiol 2006;79:652–58. Epub 2006 Apr 26

    Abstract/FREE Full Text
26. 26.↵
    1. Kim HS,
    2. Kim SY

    . A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol 2007;28:1693–99

    Abstract/FREE Full Text
27. 27.↵
    1. Kitis O,
    2. Altay H,
    3. Calli C,
    4. et al

    . Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol 2005;55:393–400

    CrossRefPubMed
28. 28.↵
    1. Tozer DJ,
    2. Jager HR,
    3. Danchaivijitr N,
    4. et al

    . Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2007;20:49–57

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Alvarez-Linera J,
    2. Benito-Leon J,
    3. Escribano J,
    4. et al

    . Predicting the histopathological grade of cerebral gliomas using high b value MR DW imaging at 3-Tesla. J Neuroimaging 2008;18:276–81. Epub 2008 May 5

    PubMed
30. 30.↵
    1. Kleinschmidt-Demasters BK,
    2. Damek DM

    . The imaging and neuropathological effects of bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol 2010;96:375–84. Epub 2009 Jul 16

    CrossRefPubMed
31. 31.↵
    1. Rees JH,
    2. Smirniotopoulos JG,
    3. Jones RV,
    4. et al

    . Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics 1996;16:1413–38. quiz 1462–63

    PubMedWeb of Science
32. 32.↵
    1. Scherer HJ

    . The forms of growth in gliomas and their practical significance. Brain 1940;63:1–35

    FREE Full Text
33. 33.↵
    1. Krishnan AP,
    2. Asher IM,
    3. Davis D,
    4. et al

    . Evidence that MR diffusion tensor imaging (tractography) predicts the natural history of regional progression in patients irradiated conformally for primary brain tumors. Int J Radiat Oncol Biol Phys 2008;71:1553–62. Epub 2008 Jun 4

    CrossRefPubMed
34. 34.↵
    1. Chen W,
    2. Delaloye S,
    3. Silverman DH,
    4. et al

    . Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714–21

    Abstract/FREE Full Text
35. 35.↵
    1. Grommes C,
    2. Akhurst TJ,
    3. Blasberg RG,
    4. et al

    . [18F]FACBC and [18F]FLT PET imaging for glioblastomas (GBM) [abstract]. Neurology 2010;74(Suppl 2):A594
36. 36.↵
    1. Stupp R,
    2. Mason WP,
    3. van den Bent MJ,
    4. et al

    . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Brandes AA,
    2. Tosoni A,
    3. Spagnolli F,
    4. et al

    . Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008;10:361–67

    Abstract/FREE Full Text
38. 38.↵
    1. Sasaki M,
    2. Yamada K,
    3. Watanabe Y,
    4. et al

    . Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 2008;249:624–30

    CrossRefPubMed